Newsroom
Newsroom
2013
2013-08-30 10:30
Obducat: Obducat participates in M-ERA.NET project developing new “smart” materials
Biosensor and microfluidic technologies are a key topic for the development of new Point-of-Care (POC) analysis system useful in the health care sector. In order to further broaden the use of these POC systems a new generation of bio analytical tools must be developed which will improve characteristics in terms of stability, sensitivity, selectivity at the same time as the manufacturing cost can be reduced. In the field of electrochemical biosensors, the development of new electrode surfaces and recognition elements with high stability, sensitivity...
2013-05-14 10:24
Obducat: Obducat receives an order for a NIL pilot manufacturing line from Kimberly-Clark
Obducat and Kimberly-Clark entered into a Joint Development Agreement in June 2011. Based on the successful joint development efforts the parties have signed a Purchase Agreement concerning a NIL (Nano Imprint Lithography) pilot manufacturing line. The pilot line will be used for production of a medical device being developed by Kimberly-Clark. The pilot line is a "first-of-its-kind" and is scheduled to be delivered during fourth quarter this year. This is information that Obducat AB (publ) is required to disclose pursuant to the Swedish...
2011
2011-06-28 09:04
Obducat signs joint development agreement with Kimberly-Clark
The target of the collaboration is to create a pilot scale NIL (Nano Imprint Lithography) solution to produce unique Kimberly-Clark devices. The application will remain undisclosed for the time being. A ramp into volume production is targeted provided that the development activities reach agreed performance criteria. This is information that Obducat AB is required to make in compliance with the Swedish Securities Market Act. The information was submitted for publication on June 28, 2011 at 08:50 CET. For further information, please contact: Patrik...
2011-04-29 08:08
Number of shares and votes in Obducat
This is information that Obducat AB is required to make in compliance with the Swedish Securities Market Act. The information was submitted for publication on April 29, 2011 at 07:30 CET. For further information, please contact: Patrik Lundström, CEO, Obducat AB, +46 40-36 21 00 or 703 - 27 37 38 Henri Bergstrand, Chairman of the Board, Obducat AB, +46 40-36 21 00 or 708 - 88 72 45 About Obducat AB Obducat AB is an innovative developer and supplier of technologies, products and processes used for the production and replication of advanced micro...
2010
2010-12-16 09:03
OBDUCAT: OBDUCAT SECURES SEK 30 MILLION EQUITY FINANCING FACILITY
2010-10-29 13:03
OBDUCAT: NUMBER OF SHARES AND VOTES IN OBDUCAT